Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
This trial showed that in patients with lymphangioleiomyomatosis (LAM), a progressive, cystic lung disease in women, sirolimus therapy was associated with stabilization of lung function, reduction in symptoms, and improvement in qualityof-life measures. Lymphangioleiomyomatosis (LAM) is an uncommon...
Saved in:
| Published in | The New England journal of medicine Vol. 364; no. 17; pp. 1595 - 1606 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Massachusetts Medical Society
28.04.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0028-4793 1533-4406 1533-4406 |
| DOI | 10.1056/NEJMoa1100391 |
Cover
Loading…
| Abstract | This trial showed that in patients with lymphangioleiomyomatosis (LAM), a progressive, cystic lung disease in women, sirolimus therapy was associated with stabilization of lung function, reduction in symptoms, and improvement in qualityof-life measures.
Lymphangioleiomyomatosis (LAM) is an uncommon systemic disease that is associated with cystic destruction of the lung, chylous pleural effusions, and abdominal tumors such as renal angiomyolipomas.
1
,
2
LAM affects women almost exclusively and occurs sporadically, developing in about 5 persons per 1 million; it also affects 30 to 40% of women with tuberous sclerosis complex (TSC). Lung function, measured as the forced expiratory volume in 1 second (FEV
1
), declines at the rate of 75 to 118 ml per year
3
–
5
; clinically important respiratory impairment, recurrent pneumothoraxes, and hypoxemia develop in most patients within a decade after the . . . |
|---|---|
| AbstractList | Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM.BACKGROUNDLymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM.We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV(1)).METHODSWe conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV(1)).During the treatment period, the FEV(1) slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the mean FEV(1) at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups.RESULTSDuring the treatment period, the FEV(1) slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the mean FEV(1) at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups.In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.).CONCLUSIONSIn patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.). This trial showed that in patients with lymphangioleiomyomatosis (LAM), a progressive, cystic lung disease in women, sirolimus therapy was associated with stabilization of lung function, reduction in symptoms, and improvement in qualityof-life measures. Lymphangioleiomyomatosis (LAM) is an uncommon systemic disease that is associated with cystic destruction of the lung, chylous pleural effusions, and abdominal tumors such as renal angiomyolipomas. 1 , 2 LAM affects women almost exclusively and occurs sporadically, developing in about 5 persons per 1 million; it also affects 30 to 40% of women with tuberous sclerosis complex (TSC). Lung function, measured as the forced expiratory volume in 1 second (FEV 1 ), declines at the rate of 75 to 118 ml per year 3 – 5 ; clinically important respiratory impairment, recurrent pneumothoraxes, and hypoxemia develop in most patients within a decade after the . . . Background Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM. Methods We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment -- a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV1 ). Results During the treatment period, the FEV1 slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV1 during the treatment period was 153 ml, or approximately 11% of the mean FEV1 at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. Conclusions In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648 .) Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM. We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV(1)). During the treatment period, the FEV(1) slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the mean FEV(1) at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.). |
| Author | Singer, Lianne G Sullivan, Eugene J Lee, Hye-Seung Cohen, Marsha M Inoue, Yoshikazu Korbee, Leslie Young, Lisa R Brown, Kevin K Kinder, Brent W Downey, Gregory P Nakata, Koh McCormack, Francis X Brantly, Mark L Lynch, Joseph P Colby, Thomas V Strange, Charlie Stocks, James M Barker, Alan F McKay, Roy T Goldberg, Hilary J Taveira-DaSilva, Angelo M Moss, Joel Trapnell, Bruce C Krischer, Jeffrey P Chapman, Jeffrey T |
| Author_xml | – sequence: 1 givenname: Francis X surname: McCormack fullname: McCormack, Francis X – sequence: 2 givenname: Yoshikazu surname: Inoue fullname: Inoue, Yoshikazu – sequence: 3 givenname: Joel surname: Moss fullname: Moss, Joel – sequence: 4 givenname: Lianne G surname: Singer fullname: Singer, Lianne G – sequence: 5 givenname: Charlie surname: Strange fullname: Strange, Charlie – sequence: 6 givenname: Koh surname: Nakata fullname: Nakata, Koh – sequence: 7 givenname: Alan F surname: Barker fullname: Barker, Alan F – sequence: 8 givenname: Jeffrey T surname: Chapman fullname: Chapman, Jeffrey T – sequence: 9 givenname: Mark L surname: Brantly fullname: Brantly, Mark L – sequence: 10 givenname: James M surname: Stocks fullname: Stocks, James M – sequence: 11 givenname: Kevin K surname: Brown fullname: Brown, Kevin K – sequence: 12 givenname: Joseph P surname: Lynch fullname: Lynch, Joseph P – sequence: 13 givenname: Hilary J surname: Goldberg fullname: Goldberg, Hilary J – sequence: 14 givenname: Lisa R surname: Young fullname: Young, Lisa R – sequence: 15 givenname: Brent W surname: Kinder fullname: Kinder, Brent W – sequence: 16 givenname: Gregory P surname: Downey fullname: Downey, Gregory P – sequence: 17 givenname: Eugene J surname: Sullivan fullname: Sullivan, Eugene J – sequence: 18 givenname: Thomas V surname: Colby fullname: Colby, Thomas V – sequence: 19 givenname: Roy T surname: McKay fullname: McKay, Roy T – sequence: 20 givenname: Marsha M surname: Cohen fullname: Cohen, Marsha M – sequence: 21 givenname: Leslie surname: Korbee fullname: Korbee, Leslie – sequence: 22 givenname: Angelo M surname: Taveira-DaSilva fullname: Taveira-DaSilva, Angelo M – sequence: 23 givenname: Hye-Seung surname: Lee fullname: Lee, Hye-Seung – sequence: 24 givenname: Jeffrey P surname: Krischer fullname: Krischer, Jeffrey P – sequence: 25 givenname: Bruce C surname: Trapnell fullname: Trapnell, Bruce C |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21410393$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1LJDEQxYO46Phx9CqNsHjq3aSTTicgwiLjfjDqQT2HmnSiGTrJ2Ole6P9-I6OyCuYSSP3q1XupPbQdYjAIHRH8jeCaf7-e_7mKQAjGVJItNCM1pSVjmG-jGcaVKFkj6S7aS2mF8yFM7qDdijCSeTpDZ3NrnQY9FRDa4hasGaYi2uLW9bFzfkyFC8Vi8utHCA8udsZFP0UPQ0wuHaAvFrpkDl_ufXR_Ob-7-FUubn7-vvixKHWN5VC2YAWnjAhZC8wxFoY1LXDZQN1SmR-ornRbtc1y2QorJFTSiKWsqK2ZkcDpPjrf6K7HpTetNmHooVPr3nnoJxXBqfeV4B7VQ_yrKCGCY5IFTl8E-vg0mjQo75I2XQfBxDEpwRnJ87DM5MkHchXHPuR0GRI8x6iaDB3_7-fNyOu3ZoBuAN3HlHpjlXYDDC4-23OdIlg9L0-9W17uKj90vQp_xn_d8N4nFczKf8L9A9Z4pe0 |
| CODEN | NEJMAG |
| CitedBy_id | crossref_primary_10_1016_j_chest_2023_09_014 crossref_primary_10_1016_j_chest_2023_02_026 crossref_primary_10_1016_j_critrevonc_2022_103749 crossref_primary_10_1183_16000617_0042_2017 crossref_primary_10_3389_fonc_2022_852859 crossref_primary_10_1016_j_ad_2012_11_020 crossref_primary_10_1007_s11255_019_02093_6 crossref_primary_10_1165_rcmb_2018_0123OC crossref_primary_10_1371_journal_pone_0155331 crossref_primary_10_3892_etm_2015_2397 crossref_primary_10_1183_13993003_01683_2015 crossref_primary_10_5761_atcs_cr_12_02179 crossref_primary_10_1016_j_drudis_2018_11_022 crossref_primary_10_1016_j_rmr_2023_08_005 crossref_primary_10_1183_09059180_00009311 crossref_primary_10_1016_j_ijid_2018_01_033 crossref_primary_10_1111_epi_17807 crossref_primary_10_1158_0008_5472_CAN_20_2218 crossref_primary_10_1002_cns3_20070 crossref_primary_10_1016_j_pharmthera_2013_12_004 crossref_primary_10_1142_S0219519417500397 crossref_primary_10_1016_j_chest_2018_06_016 crossref_primary_10_4155_cli_13_101 crossref_primary_10_1007_s12035_016_9687_7 crossref_primary_10_1586_17476348_2016_1148603 crossref_primary_10_1210_me_2013_1059 crossref_primary_10_1016_j_ctrv_2012_12_015 crossref_primary_10_1016_S1877_1203_11_70163_X crossref_primary_10_1016_j_jaip_2015_11_007 crossref_primary_10_1016_j_reth_2018_12_001 crossref_primary_10_1016_j_jaad_2015_07_018 crossref_primary_10_1016_j_iac_2012_08_004 crossref_primary_10_1016_j_ejphar_2024_176401 crossref_primary_10_1016_S1877_1203_11_70052_0 crossref_primary_10_1080_21678707_2018_1493376 crossref_primary_10_1164_rccm_201205_0848OE crossref_primary_10_1371_journal_pone_0146749 crossref_primary_10_1164_rccm_201212_2302LE crossref_primary_10_1164_rccm_202312_2254ED crossref_primary_10_1016_S2213_2600_13_70085_7 crossref_primary_10_3390_jcm13010015 crossref_primary_10_3390_jcm10163705 crossref_primary_10_1186_s13023_022_02496_2 crossref_primary_10_1016_j_rmr_2023_01_023 crossref_primary_10_1089_lrb_2011_0020 crossref_primary_10_26442_20751753_2022_3_201504 crossref_primary_10_1016_j_biomaterials_2020_120536 crossref_primary_10_1016_j_humpath_2018_05_018 crossref_primary_10_1016_j_pediatrneurol_2016_03_015 crossref_primary_10_1016_j_athoracsur_2014_11_069 crossref_primary_10_1016_j_arr_2020_101151 crossref_primary_10_48095_cccu2020008 crossref_primary_10_1161_JAHA_119_015761 crossref_primary_10_1183_09031936_00167413 crossref_primary_10_1186_s12890_018_0775_5 crossref_primary_10_1055_s_0041_1727142 crossref_primary_10_1136_thoraxjnl_2017_210872 crossref_primary_10_1007_s00108_012_3158_7 crossref_primary_10_1111_jdv_14964 crossref_primary_10_1177_0883073817696814 crossref_primary_10_15252_emmm_202113929 crossref_primary_10_1634_theoncologist_2019_0514 crossref_primary_10_1513_AnnalsATS_201610_765CC crossref_primary_10_1016_j_ijscr_2017_10_057 crossref_primary_10_1124_pharmrev_120_000030 crossref_primary_10_1016_j_healun_2021_07_005 crossref_primary_10_1016_S2213_2600_20_30225_3 crossref_primary_10_1186_s13023_024_03243_5 crossref_primary_10_1007_s12672_012_0128_4 crossref_primary_10_1056_NEJMc1106358 crossref_primary_10_1371_journal_pone_0189132 crossref_primary_10_1002_rcr2_105 crossref_primary_10_1164_rccm_201411_2096CI crossref_primary_10_1186_s13023_017_0596_2 crossref_primary_10_1038_s41388_020_01504_8 crossref_primary_10_1007_s11940_013_0249_2 crossref_primary_10_18632_oncotarget_26668 crossref_primary_10_1172_jci_insight_137708 crossref_primary_10_1002_ajmg_c_31654 crossref_primary_10_1016_j_ajpath_2012_05_017 crossref_primary_10_2169_internalmedicine_1329_18 crossref_primary_10_1002_ajmg_c_31655 crossref_primary_10_1186_s13023_022_02266_0 crossref_primary_10_1016_j_medcli_2013_05_036 crossref_primary_10_1016_S1474_4422_15_00069_1 crossref_primary_10_1164_rccm_201405_0918OC crossref_primary_10_1172_jci_insight_126703 crossref_primary_10_1183_23120541_00102_2015 crossref_primary_10_1186_s13023_014_0182_9 crossref_primary_10_1590_S1806_37132015000004553 crossref_primary_10_1186_s13023_024_03115_y crossref_primary_10_1016_j_prp_2022_153758 crossref_primary_10_1016_j_biocel_2014_03_024 crossref_primary_10_1002_cjp2_162 crossref_primary_10_1097_CAD_0000000000000634 crossref_primary_10_1126_scitranslmed_3003840 crossref_primary_10_1172_jci_insight_86629 crossref_primary_10_1038_s41467_023_44229_4 crossref_primary_10_1183_13993003_03036_2020 crossref_primary_10_1016_j_semcdb_2016_01_025 crossref_primary_10_1152_ajplung_00305_2012 crossref_primary_10_3390_ijms22094371 crossref_primary_10_1186_s13023_022_02418_2 crossref_primary_10_3892_ijo_2022_5422 crossref_primary_10_1016_j_chest_2017_05_018 crossref_primary_10_1007_s13665_020_00248_w crossref_primary_10_1590_S1806_37132013000100002 crossref_primary_10_1177_2050313X20921332 crossref_primary_10_1183_09031936_00076411 crossref_primary_10_1165_rcmb_2023_0410OC crossref_primary_10_1007_s10585_012_9493_1 crossref_primary_10_1016_j_atssr_2024_07_011 crossref_primary_10_1038_s41598_021_88064_3 crossref_primary_10_1016_S1470_2045_14_71101_5 crossref_primary_10_1007_s15033_015_0224_6 crossref_primary_10_1080_08998280_2024_2334629 crossref_primary_10_1093_hmg_ddx345 crossref_primary_10_1164_rccm_201709_1965ST crossref_primary_10_1183_16000617_0004_2016 crossref_primary_10_1371_journal_pone_0054426 crossref_primary_10_1590_S1806_37132011000400002 crossref_primary_10_1016_j_arbr_2011_06_016 crossref_primary_10_1083_jcb_202305005 crossref_primary_10_1590_S1806_37132011000400003 crossref_primary_10_3892_ijo_2015_2913 crossref_primary_10_1080_21678707_2017_1400966 crossref_primary_10_1186_s12886_022_02334_w crossref_primary_10_1053_j_ro_2014_04_007 crossref_primary_10_1177_17407745231158906 crossref_primary_10_1183_23120541_00038_2022 crossref_primary_10_1183_16000617_0163_2019 crossref_primary_10_1186_s13023_017_0581_9 crossref_primary_10_1007_s10405_019_00290_9 crossref_primary_10_1007_s11739_012_0833_6 crossref_primary_10_1016_j_rppnen_2012_04_008 crossref_primary_10_3904_kjim_2016_242 crossref_primary_10_1007_s15033_019_1341_4 crossref_primary_10_1016_j_healun_2011_12_004 crossref_primary_10_1615_CritRevOncog_2022042857 crossref_primary_10_1007_s00428_014_1559_9 crossref_primary_10_1164_rccm_201807_1212CI crossref_primary_10_1183_16000617_0101_2024 crossref_primary_10_1039_D0NP00024H crossref_primary_10_1097_PAS_0000000000000416 crossref_primary_10_1016_j_resinv_2014_02_004 crossref_primary_10_1183_13993003_00951_2018 crossref_primary_10_1146_annurev_physiol_020518_114640 crossref_primary_10_1183_23120541_00375_2021 crossref_primary_10_1378_chest_14_0758 crossref_primary_10_1016_j_jns_2013_05_029 crossref_primary_10_1183_13993003_00412_2015 crossref_primary_10_1016_j_bbamcr_2016_03_009 crossref_primary_10_1186_s12955_015_0294_5 crossref_primary_10_1517_21678707_2015_1022529 crossref_primary_10_1371_journal_pone_0132546 crossref_primary_10_1097_MCP_0000000000000391 crossref_primary_10_1002_pbc_29510 crossref_primary_10_1016_j_chest_2019_08_005 crossref_primary_10_1002_dc_24802 crossref_primary_10_1186_s11689_024_09543_y crossref_primary_10_1530_ERC_15_0505 crossref_primary_10_1513_AnnalsATS_201610_824OC crossref_primary_10_1136_thoraxjnl_2019_213338 crossref_primary_10_1126_sciadv_adf8549 crossref_primary_10_1183_13993003_02370_2019 crossref_primary_10_1158_1078_0432_CCR_17_3693 crossref_primary_10_1016_j_jss_2024_08_026 crossref_primary_10_1158_1535_7163_MCT_22_0224 crossref_primary_10_7759_cureus_73365 crossref_primary_10_1016_j_resinv_2013_11_002 crossref_primary_10_7759_cureus_40217 crossref_primary_10_1371_journal_pone_0180939 crossref_primary_10_1080_0284186X_2019_1589648 crossref_primary_10_1136_bcr_2024_260369 crossref_primary_10_1016_j_chest_2017_05_012 crossref_primary_10_1016_j_resinv_2014_02_002 crossref_primary_10_1016_j_chest_2023_01_007 crossref_primary_10_3389_fped_2023_1109646 crossref_primary_10_1016_j_diii_2013_01_003 crossref_primary_10_1111_acel_12256 crossref_primary_10_1002_ana_24523 crossref_primary_10_1002_pbc_24832 crossref_primary_10_1007_s00467_014_3027_9 crossref_primary_10_1016_j_purol_2012_03_006 crossref_primary_10_1186_s11658_024_00638_x crossref_primary_10_4187_respcare_07117 crossref_primary_10_26508_lsa_202201369 crossref_primary_10_1183_09031936_00025314 crossref_primary_10_3390_ijms21093151 crossref_primary_10_1183_09031936_00093111 crossref_primary_10_1093_brain_awz370 crossref_primary_10_1165_rcmb_2014_0033OC crossref_primary_10_1016_j_chest_2016_02_652 crossref_primary_10_1038_s41467_020_18979_4 crossref_primary_10_1378_chest_14_0380 crossref_primary_10_1164_rccm_201810_1895ST crossref_primary_10_3389_fphar_2022_802334 crossref_primary_10_1177_1066896915606971 crossref_primary_10_1016_j_pog_2012_05_010 crossref_primary_10_1126_scisignal_aab3729 crossref_primary_10_1002_ana_23960 crossref_primary_10_1016_j_chest_2016_02_654 crossref_primary_10_1183_16000617_0161_2022 crossref_primary_10_1038_s41416_020_01039_5 crossref_primary_10_1073_pnas_1719960115 crossref_primary_10_1159_000448293 crossref_primary_10_1371_journal_pone_0105365 crossref_primary_10_1210_endocr_bqad093 crossref_primary_10_1164_rccm_201703_0584ED crossref_primary_10_1111_crj_13108 crossref_primary_10_1093_qjmed_hcy215 crossref_primary_10_3389_fmolb_2023_1000248 crossref_primary_10_1016_j_semcdb_2014_09_018 crossref_primary_10_1080_21678707_2020_1789862 crossref_primary_10_1084_jem_20190251 crossref_primary_10_1523_ENEURO_0436_17_2018 crossref_primary_10_1186_s40792_022_01507_5 crossref_primary_10_1111_1348_0421_12321 crossref_primary_10_1007_s00408_014_9641_2 crossref_primary_10_1002_advs_202302611 crossref_primary_10_1016_j_drudis_2021_12_009 crossref_primary_10_1517_14656566_2015_1074176 crossref_primary_10_1093_neuonc_nov152 crossref_primary_10_1016_S0140_6736_12_61767_X crossref_primary_10_1016_S1134_2072_13_70684_4 crossref_primary_10_1016_S2213_2600_21_00228_9 crossref_primary_10_1016_j_pediatrneurol_2012_02_015 crossref_primary_10_1158_1541_7786_MCR_17_0077 crossref_primary_10_1007_s13546_012_0642_y crossref_primary_10_1371_journal_pone_0032468 crossref_primary_10_1513_AnnalsATS_201512_818ED crossref_primary_10_1021_acs_chemrev_4c00577 crossref_primary_10_1038_s41467_022_32673_7 crossref_primary_10_1172_JCI84262 crossref_primary_10_1007_s15033_018_1106_5 crossref_primary_10_1016_j_isci_2021_102684 crossref_primary_10_1016_j_rmcr_2018_01_002 crossref_primary_10_1183_13993003_00398_2016 crossref_primary_10_3390_genes13111932 crossref_primary_10_1165_rcmb_2013_0171OC crossref_primary_10_1378_chest_12_1247 crossref_primary_10_3389_fimmu_2022_844914 crossref_primary_10_3389_fimmu_2024_1425988 crossref_primary_10_1002_path_4827 crossref_primary_10_1007_s00330_024_10649_z crossref_primary_10_1016_j_jbc_2022_102580 crossref_primary_10_1007_s13577_024_01165_9 crossref_primary_10_1093_annonc_mds349 crossref_primary_10_1016_j_cell_2013_04_023 crossref_primary_10_1111_jcmm_12593 crossref_primary_10_1186_s13023_018_0874_7 crossref_primary_10_1007_s11255_012_0292_z crossref_primary_10_1016_j_resinv_2015_11_003 crossref_primary_10_1016_j_ogc_2016_01_003 crossref_primary_10_1074_jbc_M117_799593 crossref_primary_10_1164_rccm_201408_1480LE crossref_primary_10_1164_rccm_202007_2854OC crossref_primary_10_1016_j_conb_2012_04_008 crossref_primary_10_3389_fmed_2024_1494713 crossref_primary_10_1016_j_chest_2019_01_004 crossref_primary_10_1016_S2213_2600_13_70090_0 crossref_primary_10_53126_MEB40443 crossref_primary_10_1016_j_pneumo_2018_10_005 crossref_primary_10_1186_s12935_020_1131_4 crossref_primary_10_1007_s40263_021_00839_4 crossref_primary_10_1016_j_resinv_2015_06_003 crossref_primary_10_1136_jclinpath_2012_201297 crossref_primary_10_1186_s13023_021_02081_z crossref_primary_10_3389_fped_2023_1263631 crossref_primary_10_7554_eLife_23202 crossref_primary_10_3390_biom14091190 crossref_primary_10_1016_j_chest_2017_07_027 crossref_primary_10_3390_cancers14071637 crossref_primary_10_1183_13993003_00664_2021 crossref_primary_10_1513_AnnalsATS_201509_631OC crossref_primary_10_1371_journal_pone_0212776 crossref_primary_10_3892_br_2016_652 crossref_primary_10_1097_MD_0000000000011119 crossref_primary_10_1007_s11684_018_0634_z crossref_primary_10_1172_jci_insight_166850 crossref_primary_10_1016_j_cub_2018_04_061 crossref_primary_10_1016_j_iac_2023_01_003 crossref_primary_10_1056_NEJMe1102290 crossref_primary_10_1038_s41392_023_01502_8 crossref_primary_10_14309_crj_0000000000000517 crossref_primary_10_1164_ajrccm_187_6_663 crossref_primary_10_1186_s12890_016_0286_1 crossref_primary_10_1016_S1877_1203_13_70361_6 crossref_primary_10_12688_wellcomeopenres_17845_1 crossref_primary_10_3389_fmed_2021_584826 crossref_primary_10_1177_17562864221138148 crossref_primary_10_3390_cells11182862 crossref_primary_10_1111_pin_12028 crossref_primary_10_12688_wellcomeopenres_17845_3 crossref_primary_10_12688_wellcomeopenres_17845_2 crossref_primary_10_1542_peds_2015_3257 crossref_primary_10_1016_j_det_2022_06_013 crossref_primary_10_1136_thoraxjnl_2019_214241 crossref_primary_10_1016_j_healun_2022_09_021 crossref_primary_10_1111_trf_16064 crossref_primary_10_1136_thoraxjnl_2021_217809 crossref_primary_10_1378_chest_12_0161 crossref_primary_10_1186_1824_7288_39_57 crossref_primary_10_1186_s13023_020_1344_6 crossref_primary_10_1212_WNL_0000000000003400 crossref_primary_10_1080_14737140_2018_1500180 crossref_primary_10_1158_1541_7786_MCR_14_0343 crossref_primary_10_3389_fncel_2018_00201 crossref_primary_10_1165_rcmb_2017_0403TR crossref_primary_10_1080_19466315_2022_2118162 crossref_primary_10_1186_s13023_018_0775_9 crossref_primary_10_1007_s13555_023_00914_2 crossref_primary_10_1007_s00381_022_05446_2 crossref_primary_10_1513_AnnalsATS_201609_680AW crossref_primary_10_1165_rcmb_2013_0315LE crossref_primary_10_1097_PAS_0000000000000133 crossref_primary_10_1016_j_ejrad_2012_05_033 crossref_primary_10_1183_13993003_00405_2022 crossref_primary_10_3390_jcm13226887 crossref_primary_10_1016_j_pain_2013_03_021 crossref_primary_10_1016_j_resinv_2013_03_002 crossref_primary_10_1164_rccm_201411_2094CI crossref_primary_10_1378_chest_12_1044 crossref_primary_10_1165_rcmb_2011_0215TR crossref_primary_10_1172_jci_insight_187899 crossref_primary_10_1016_j_rmed_2020_105898 crossref_primary_10_1164_rccm_201512_2468SO crossref_primary_10_1111_nyas_12756 crossref_primary_10_1152_ajplung_00365_2015 crossref_primary_10_1055_a_2051_8395 crossref_primary_10_1186_s12931_022_02022_9 crossref_primary_10_4046_trd_2013_74_3_97 crossref_primary_10_1097_ACM_0b013e31829ed2a7 crossref_primary_10_1172_JCI64227 crossref_primary_10_1007_s00408_017_0045_y crossref_primary_10_1089_neu_2017_5184 crossref_primary_10_17650_2313_805X_2019_6_2_28_41 crossref_primary_10_5500_wjt_v6_i1_249 crossref_primary_10_1016_j_chest_2018_09_013 crossref_primary_10_1007_s15033_015_0060_8 crossref_primary_10_1038_nm_2545 crossref_primary_10_1038_s41392_023_01723_x crossref_primary_10_1158_1541_7786_MCR_14_0440 crossref_primary_10_1016_j_resinv_2022_01_001 crossref_primary_10_1016_j_ijrobp_2016_07_026 crossref_primary_10_1016_j_clindermatol_2015_11_003 crossref_primary_10_1007_s12672_014_0192_z crossref_primary_10_1586_14737175_2016_1151788 crossref_primary_10_1016_S1877_1203_12_70274_4 crossref_primary_10_18632_oncotarget_10748 crossref_primary_10_1016_j_mpmed_2012_03_007 crossref_primary_10_1093_hmg_dds262 crossref_primary_10_12688_f1000research_14564_1 crossref_primary_10_1172_JCI167861 crossref_primary_10_1183_09031936_00221914 crossref_primary_10_1007_s00330_019_06412_4 crossref_primary_10_1089_lrb_2021_0103 crossref_primary_10_1016_j_pharmthera_2015_12_008 crossref_primary_10_1111_bcp_12834 crossref_primary_10_1136_bcr_2018_226358 crossref_primary_10_1016_j_chest_2022_12_027 crossref_primary_10_1016_j_resinv_2018_07_004 crossref_primary_10_7759_cureus_25871 crossref_primary_10_1007_s13311_015_0359_5 crossref_primary_10_1186_s13023_016_0553_5 crossref_primary_10_1021_acsptsci_2c00006 crossref_primary_10_1016_j_rmed_2012_10_006 crossref_primary_10_1164_rccm_201607_1384ST crossref_primary_10_1183_13993003_00568_2016 crossref_primary_10_1126_sciadv_aay9131 crossref_primary_10_1378_chest_12_2813 crossref_primary_10_1016_j_mvr_2014_08_007 crossref_primary_10_1038_ejhg_2015_47 crossref_primary_10_14309_ajg_0000000000001117 crossref_primary_10_1016_S1877_1203_12_70177_5 crossref_primary_10_1586_17476348_2014_956728 crossref_primary_10_1136_bcr_2018_226244 crossref_primary_10_1093_qjmed_hcu019 crossref_primary_10_1007_s00330_024_10765_w crossref_primary_10_1038_onc_2016_264 crossref_primary_10_1073_pnas_2116271119 crossref_primary_10_1002_bmc_4853 crossref_primary_10_1001_jamadermatol_2018_1408 crossref_primary_10_1016_j_transproceed_2015_12_021 crossref_primary_10_1016_j_chest_2018_02_027 crossref_primary_10_3390_ijerph18094907 crossref_primary_10_1097_RTI_0000000000000601 crossref_primary_10_1016_j_arbr_2016_04_002 crossref_primary_10_1183_13993003_02258_2017 crossref_primary_10_1136_thoraxjnl_2017_211169 crossref_primary_10_1158_0008_5472_CAN_16_2755 crossref_primary_10_1165_rcmb_2024_0266ED crossref_primary_10_1186_1465_9921_13_34 crossref_primary_10_1186_1465_9921_12_66 crossref_primary_10_1159_000516330 crossref_primary_10_1177_1758835919846798 crossref_primary_10_1038_s41598_021_85999_5 crossref_primary_10_1007_s00277_024_05783_z crossref_primary_10_14814_phy2_13983 crossref_primary_10_1016_j_chest_2022_03_006 crossref_primary_10_1016_j_pediatrneurol_2013_08_002 crossref_primary_10_1016_j_oret_2022_01_003 crossref_primary_10_1021_acs_jmedchem_8b01262 crossref_primary_10_1186_s13256_025_05174_6 crossref_primary_10_1007_s10522_021_09910_5 crossref_primary_10_1056_NEJMc1803858 crossref_primary_10_1161_ATVBAHA_118_312315 crossref_primary_10_1007_s11606_014_2894_x crossref_primary_10_1016_j_ejpn_2018_06_007 crossref_primary_10_1146_annurev_med_050715_104245 crossref_primary_10_1158_1541_7786_MCR_12_0605 crossref_primary_10_1111_bcpt_13027 crossref_primary_10_1158_1940_6207_CAPR_14_0142 crossref_primary_10_1513_AnnalsATS_202006_702RL crossref_primary_10_1016_j_ccm_2011_12_003 crossref_primary_10_1097_MCP_0000000000000502 crossref_primary_10_18632_aging_103493 crossref_primary_10_1158_0008_5472_CAN_13_1256 crossref_primary_10_1172_JCI58709 crossref_primary_10_1007_s12253_020_00796_1 crossref_primary_10_1620_tjem_2023_J016 crossref_primary_10_36416_1806_3756_e20240378 crossref_primary_10_1183_09059180_00008813 crossref_primary_10_1016_j_rmed_2012_02_016 crossref_primary_10_1016_j_rmed_2013_04_022 crossref_primary_10_1038_cddis_2014_204 crossref_primary_10_1016_j_chest_2022_03_016 crossref_primary_10_1097_MD_0000000000020710 crossref_primary_10_1111_bcp_12928 crossref_primary_10_1165_rcmb_2023_0327ED crossref_primary_10_1002_jso_24893 crossref_primary_10_1165_rcmb_2013_0203RC crossref_primary_10_5833_jjgs_2013_0071 crossref_primary_10_1007_s11906_017_0783_5 crossref_primary_10_1165_rcmb_2015_0022OC crossref_primary_10_1002_ajmg_a_37148 crossref_primary_10_1513_AnnalsATS_201610_814ED crossref_primary_10_1016_j_adengl_2016_03_001 crossref_primary_10_1016_j_bbrc_2021_07_080 crossref_primary_10_1186_1477_7525_12_79 crossref_primary_10_1183_13993003_00863_2019 crossref_primary_10_3748_wjg_v26_i45_7263 crossref_primary_10_1002_ijc_27800 crossref_primary_10_3390_cancers17020323 crossref_primary_10_1007_s11427_022_2102_3 crossref_primary_10_1084_jem_20131080 crossref_primary_10_3390_ijms24065276 crossref_primary_10_1021_acs_jmedchem_1c00963 crossref_primary_10_1080_17476348_2018_1409622 crossref_primary_10_1513_AnnalsATS_201605_335OC crossref_primary_10_1007_s11560_025_00833_7 crossref_primary_10_1016_j_chest_2022_05_036 crossref_primary_10_3389_fncel_2019_00518 crossref_primary_10_3390_biomedicines10040826 crossref_primary_10_1016_j_chest_2024_08_008 crossref_primary_10_1016_j_phrs_2019_03_006 crossref_primary_10_1053_j_semdp_2013_11_003 crossref_primary_10_1007_s10405_012_0648_1 crossref_primary_10_1007_s11357_023_00851_0 crossref_primary_10_1016_j_arbres_2015_02_013 crossref_primary_10_1089_lrb_2011_9302 crossref_primary_10_1182_blood_2015_01_620377 crossref_primary_10_5694_mja12_11567 crossref_primary_10_1038_s41581_018_0059_6 crossref_primary_10_1155_2015_315240 crossref_primary_10_1093_omcr_omx023 crossref_primary_10_1016_j_ejpb_2014_05_008 crossref_primary_10_7861_clinmedicine_12_6_s7 crossref_primary_10_1016_j_resmer_2019_09_001 crossref_primary_10_1681_ASN_0000000000000146 crossref_primary_10_1136_thoraxjnl_2017_211135 crossref_primary_10_1378_chest_11_1913 crossref_primary_10_1007_s10405_017_0100_7 crossref_primary_10_3390_ijms23137040 crossref_primary_10_1038_onc_2013_401 crossref_primary_10_1016_j_chest_2019_05_038 crossref_primary_10_1016_j_heliyon_2020_e03345 crossref_primary_10_1016_j_hoc_2013_07_011 crossref_primary_10_1016_j_spen_2015_10_006 crossref_primary_10_1016_j_hoc_2013_07_009 crossref_primary_10_1016_j_pediatrneurol_2013_08_017 crossref_primary_10_1080_21678707_2017_1391089 crossref_primary_10_1586_17476348_2015_1024663 crossref_primary_10_1590_1678_4685_gmb_2020_0014 crossref_primary_10_1038_cddis_2014_502 crossref_primary_10_1186_s13023_019_1178_2 crossref_primary_10_1186_s12931_020_1316_3 crossref_primary_10_4103_2045_8932_109940 crossref_primary_10_1164_rccm_201912_2445OC crossref_primary_10_1016_j_resmer_2023_101010 crossref_primary_10_1016_j_chest_2018_08_1029 crossref_primary_10_1159_000440939 crossref_primary_10_1007_s13311_014_0320_z crossref_primary_10_3389_fcell_2014_00069 crossref_primary_10_1136_bcr_2022_251513 crossref_primary_10_1513_AnnalsATS_201212_125OC crossref_primary_10_1152_ajplung_00072_2013 crossref_primary_10_1513_AnnalsATS_201812_880OC crossref_primary_10_1016_S1877_1203_16_30083_0 crossref_primary_10_1038_s41598_019_39418_5 crossref_primary_10_1177_1756287216641353 crossref_primary_10_1097_MD_0000000000004562 crossref_primary_10_1152_japplphysiol_00737_2011 crossref_primary_10_1002_ijc_35207 crossref_primary_10_1016_j_aller_2013_10_004 crossref_primary_10_1093_hmg_ddr393 crossref_primary_10_1159_000485106 crossref_primary_10_1016_j_ad_2015_12_006 crossref_primary_10_1155_2015_394257 crossref_primary_10_1183_13993003_04270_2020 crossref_primary_10_1016_j_biomaterials_2016_05_040 crossref_primary_10_1164_rccm_201702_0272LE crossref_primary_10_1371_journal_pone_0197105 crossref_primary_10_1007_s00408_015_9742_6 crossref_primary_10_1186_s13023_024_03260_4 crossref_primary_10_1016_j_chest_2019_11_035 crossref_primary_10_1016_j_rmed_2015_08_014 crossref_primary_10_1183_16000617_0100_2023 crossref_primary_10_1016_j_rmcr_2015_02_001 crossref_primary_10_1002_pds_4259 crossref_primary_10_1016_j_chest_2017_01_033 crossref_primary_10_1038_nrdp_2016_35 crossref_primary_10_1016_j_critrevonc_2020_102960 crossref_primary_10_1371_journal_pone_0031900 crossref_primary_10_1056_NEJMms1207114 crossref_primary_10_1136_jmg_2023_109717 crossref_primary_10_1186_s12883_016_0658_4 crossref_primary_10_15252_emmm_202012822 crossref_primary_10_1080_17476348_2024_2403498 crossref_primary_10_1007_s00408_012_9419_3 crossref_primary_10_1016_j_healun_2019_06_015 crossref_primary_10_1007_s10405_015_0020_3 crossref_primary_10_1016_j_resinv_2024_05_008 crossref_primary_10_1097_MPG_0000000000000247 crossref_primary_10_1016_j_brainresbull_2019_04_016 crossref_primary_10_7759_cureus_69549 crossref_primary_10_1371_journal_pone_0056199 crossref_primary_10_1007_s11864_012_0194_4 crossref_primary_10_1172_jci_insight_90103 crossref_primary_10_1016_j_amjms_2016_11_028 crossref_primary_10_1016_j_rmr_2015_10_005 crossref_primary_10_1016_S1877_1203_18_30051_X crossref_primary_10_1016_j_neuron_2014_09_034 crossref_primary_10_1152_ajprenal_00525_2013 crossref_primary_10_1158_1541_7786_MCR_21_0220 crossref_primary_10_36416_1806_3756_e20210337 crossref_primary_10_3390_ijms22168564 crossref_primary_10_1097_MPH_0000000000000514 crossref_primary_10_1186_s42047_021_00095_2 crossref_primary_10_1007_s12013_022_01094_0 crossref_primary_10_1053_j_semdp_2023_09_001 crossref_primary_10_1016_j_lpm_2023_104173 crossref_primary_10_1159_000444264 crossref_primary_10_1016_j_lfs_2019_117157 crossref_primary_10_1016_j_echo_2018_06_003 crossref_primary_10_1183_13993003_00938_2019 crossref_primary_10_1016_S1474_4422_22_00213_7 crossref_primary_10_1093_ndt_gft009 crossref_primary_10_1016_j_isci_2022_105458 crossref_primary_10_1016_j_rmed_2015_09_005 crossref_primary_10_1016_j_ccm_2021_04_014 crossref_primary_10_1038_s41598_018_32256_x crossref_primary_10_1118_1_4916655 crossref_primary_10_1016_j_abd_2023_11_004 crossref_primary_10_1513_AnnalsATS_201606_459OC crossref_primary_10_1186_s13023_018_0933_0 crossref_primary_10_1016_j_adengl_2014_05_001 crossref_primary_10_4274_uob_galenos_2023_2023_3_2 crossref_primary_10_1016_j_ccm_2022_10_001 crossref_primary_10_3109_15412555_2013_771023 crossref_primary_10_1093_jscr_rjv140 crossref_primary_10_1136_thorax_2022_219738 crossref_primary_10_1378_chest_14_3095 crossref_primary_10_3389_fmed_2021_691688 crossref_primary_10_1590_S1806_37132011000300015 crossref_primary_10_18632_oncotarget_3793 crossref_primary_10_1016_j_thorsurg_2022_01_002 crossref_primary_10_1378_chest_13_1071 crossref_primary_10_3389_fmed_2020_554134 crossref_primary_10_1016_j_jradio_2013_01_001 crossref_primary_10_1152_ajplung_00414_2011 crossref_primary_10_2169_internalmedicine_2847_23 crossref_primary_10_70172_pjcd_v22i1_9227 crossref_primary_10_3109_08977194_2012_704917 crossref_primary_10_1016_S1665_2681_19_31498_X crossref_primary_10_1186_2049_6958_6_5_313 crossref_primary_10_1016_j_ajpath_2016_03_009 crossref_primary_10_1016_j_jdermsci_2019_05_002 crossref_primary_10_1158_1078_0432_CCR_11_0445 crossref_primary_10_1155_2019_2172163 crossref_primary_10_1002_pbc_25365 crossref_primary_10_1038_bjc_2015_261 crossref_primary_10_1016_j_cell_2017_07_029 crossref_primary_10_1002_pbc_29603 crossref_primary_10_5582_bst_2016_01220 crossref_primary_10_1016_j_rppneu_2012_02_005 crossref_primary_10_1111_1346_8138_14231 crossref_primary_10_1186_s13023_018_0946_8 crossref_primary_10_3390_ijms22052233 crossref_primary_10_1136_thoraxjnl_2022_218772 crossref_primary_10_1183_13993003_02066_2018 crossref_primary_10_1186_s12931_024_02685_6 crossref_primary_10_1016_j_revmed_2021_03_003 crossref_primary_10_1186_s13023_020_01490_w crossref_primary_10_1097_MCP_0b013e328349ac8c crossref_primary_10_1371_journal_pone_0060014 crossref_primary_10_1186_1750_1172_7_87 crossref_primary_10_1016_S2213_2600_24_00217_0 crossref_primary_10_1007_s00408_017_0016_3 crossref_primary_10_1183_20734735_0007_2020 crossref_primary_10_1172_JCI64099 crossref_primary_10_1155_2018_5928231 crossref_primary_10_1517_21678707_2014_953481 crossref_primary_10_1164_rccm_201411_2032ED crossref_primary_10_1007_s00467_016_3474_6 crossref_primary_10_1038_s41379_021_00922_7 crossref_primary_10_3389_fneur_2019_01144 crossref_primary_10_1084_jem_20140341 crossref_primary_10_1371_journal_pone_0167384 crossref_primary_10_1097_MD_0000000000021659 crossref_primary_10_1186_1750_1172_7_79 crossref_primary_10_1164_ajrccm_186_4_389 crossref_primary_10_3390_genes12101585 crossref_primary_10_1177_1526924819835815 crossref_primary_10_1586_ers_12_26 crossref_primary_10_1080_17460441_2017_1349750 crossref_primary_10_1038_s41598_022_12314_1 crossref_primary_10_2478_bjmg_2020_0017 crossref_primary_10_1016_j_humpath_2017_08_035 crossref_primary_10_1164_rccm_202401_0238SO crossref_primary_10_1165_rcmb_2011_0381ED crossref_primary_10_1007_s00404_024_07510_5 crossref_primary_10_1148_rg_220040 crossref_primary_10_1183_13993003_01886_2018 crossref_primary_10_1016_j_epsc_2016_03_014 crossref_primary_10_1016_S0304_5412_14_70854_6 crossref_primary_10_1371_journal_pone_0038589 crossref_primary_10_1007_s13555_020_00387_7 crossref_primary_10_1007_s00428_012_1305_0 crossref_primary_10_1016_j_trsl_2021_10_003 crossref_primary_10_1002_rcr2_1303 crossref_primary_10_1016_S0140_6736_16_31576_8 crossref_primary_10_1038_s41392_023_01608_z crossref_primary_10_1136_bcr_2014_205701 crossref_primary_10_1016_j_ebiom_2014_12_011 crossref_primary_10_1177_1536867X211045512 crossref_primary_10_1371_journal_pone_0292086 crossref_primary_10_1002_adma_201806214 crossref_primary_10_1007_s11739_014_1168_2 crossref_primary_10_5223_pghn_2021_24_5_413 crossref_primary_10_54105_ijpmh_B1052_05011124 crossref_primary_10_1016_j_ajpath_2013_04_002 crossref_primary_10_1200_JCO_2012_45_3019 crossref_primary_10_1111_resp_12430 crossref_primary_10_3390_molecules26020425 crossref_primary_10_1016_j_resmer_2019_02_002 crossref_primary_10_1183_13993003_01200_2024 crossref_primary_10_3389_fonc_2024_1357980 crossref_primary_10_1111_j_1582_4934_2011_01461_x crossref_primary_10_1007_s00210_022_02276_6 crossref_primary_10_1164_rccm_202104_0872ED crossref_primary_10_1016_j_ejps_2019_105098 crossref_primary_10_1038_s41419_022_05511_3 crossref_primary_10_1001_jama_2018_20926 crossref_primary_10_1016_S2213_2600_13_70098_5 crossref_primary_10_1080_17425247_2022_2029401 crossref_primary_10_1590_S1806_37132012000300002 crossref_primary_10_1016_j_det_2019_05_015 crossref_primary_10_1183_16000617_0348_2020 crossref_primary_10_1016_j_rmcr_2020_101310 crossref_primary_10_3390_biom10010028 crossref_primary_10_1016_j_reth_2018_11_001 crossref_primary_10_1016_j_humpath_2015_02_019 crossref_primary_10_1038_ncomms15816 crossref_primary_10_3390_jpm13040607 crossref_primary_10_1378_chest_11_1094 crossref_primary_10_1158_0008_5472_CAN_15_1287 crossref_primary_10_1183_20734735_0027_2021 crossref_primary_10_1021_acs_molpharmaceut_9b00263 crossref_primary_10_1002_ijc_29707 crossref_primary_10_1016_j_ajpath_2017_04_014 crossref_primary_10_1097_CCO_0b013e32835ff362 crossref_primary_10_1165_rcmb_2020_0049ED crossref_primary_10_24911_ejmcr_173_1664549057 crossref_primary_10_1002_ajmg_c_31638 crossref_primary_10_1016_j_revmed_2011_06_008 crossref_primary_10_1183_09031936_00210714 crossref_primary_10_1016_j_transproceed_2018_03_028 crossref_primary_10_4161_15384101_2014_986394 crossref_primary_10_18632_aging_103673 crossref_primary_10_3389_fonc_2022_871723 crossref_primary_10_1016_j_mehy_2020_109703 crossref_primary_10_1007_s00246_024_03420_0 crossref_primary_10_1093_jnen_nlx032 crossref_primary_10_1007_s11684_013_0269_z crossref_primary_10_1016_j_arr_2021_101376 crossref_primary_10_1155_2017_9820181 crossref_primary_10_1016_j_arbres_2024_09_005 crossref_primary_10_2169_internalmedicine_8645_16 crossref_primary_10_1111_jcpt_13631 crossref_primary_10_12688_f1000research_11110_1 crossref_primary_10_1100_2011_263137 crossref_primary_10_1016_j_humpath_2018_07_002 crossref_primary_10_1016_S1877_1203_17_30009_5 crossref_primary_10_3390_biom8010001 crossref_primary_10_1016_j_rmed_2022_106779 crossref_primary_10_3389_fmed_2024_1513619 crossref_primary_10_1038_s41598_021_89562_0 crossref_primary_10_1183_09031936_00008114 crossref_primary_10_1148_ryct_2020190097 crossref_primary_10_1056_NEJMcibr1406613 crossref_primary_10_3390_ijms25052587 crossref_primary_10_1016_j_arbres_2011_06_008 crossref_primary_10_3109_13625187_2013_859667 crossref_primary_10_1016_j_jtcvs_2024_08_038 crossref_primary_10_1164_rccm_202006_2436ED crossref_primary_10_1016_j_pcl_2015_03_005 crossref_primary_10_1161_ATVBAHA_118_311549 crossref_primary_10_7759_cureus_58805 crossref_primary_10_1007_s11684_012_0231_5 crossref_primary_10_1016_j_jid_2021_02_754 crossref_primary_10_2147_JMDH_S266990 crossref_primary_10_1016_j_nbd_2015_04_018 crossref_primary_10_1164_rccm_201712_2566LE crossref_primary_10_1016_j_ccm_2013_08_005 crossref_primary_10_1016_j_jep_2016_03_069 crossref_primary_10_1016_S1761_2896_15_72848_7 crossref_primary_10_1183_09031936_00088314 crossref_primary_10_1183_13993003_00570_2015 crossref_primary_10_1152_ajpcell_00202_2022 crossref_primary_10_1172_JCI126091 crossref_primary_10_1016_j_ccm_2011_11_001 crossref_primary_10_1038_s41598_018_32795_3 crossref_primary_10_1186_1465_9921_15_26 crossref_primary_10_1186_s13023_023_03013_9 crossref_primary_10_1517_21678707_2016_1127158 crossref_primary_10_2106_JBJS_CC_17_00287 crossref_primary_10_1513_AnnalsATS_201705_406WS crossref_primary_10_1080_21678707_2019_1662295 crossref_primary_10_1155_2014_904581 crossref_primary_10_1016_j_cmet_2014_01_001 crossref_primary_10_1016_j_rmcr_2024_102015 crossref_primary_10_1016_j_ccm_2016_04_002 crossref_primary_10_1016_j_rmcr_2018_11_010 crossref_primary_10_1016_j_ccm_2016_04_004 crossref_primary_10_1371_journal_pone_0104809 crossref_primary_10_1016_S0304_5412_14_70852_2 crossref_primary_10_1038_s41419_025_07332_6 crossref_primary_10_1111_jog_12628 crossref_primary_10_1016_j_clinimag_2024_110332 crossref_primary_10_1016_j_canep_2019_06_004 crossref_primary_10_2169_internalmedicine_56_7769 crossref_primary_10_1016_j_rmcr_2021_101505 crossref_primary_10_1073_pnas_1309110110 crossref_primary_10_1016_j_rmed_2013_08_045 crossref_primary_10_1165_rcmb_2018_0251ED |
| Cites_doi | 10.1891/1061-3749.6.1.55 10.1378/chest.10-0573 10.1002/gcc.20118 10.1053/hupa.2003.50 10.1074/jbc.M202678200 10.1056/NEJMc072500 10.1378/chest.130.4.1117 10.1164/rccm.200208-969OC 10.1097/01.pas.0000172192.25295.45 10.1097/00005792-199909000-00004 10.1073/pnas.0407971101 10.1097/01.pas.0000126859.70814.6d 10.1056/NEJMe0707153 10.1164/rccm.200409-1298OC 10.1177/107327480601300405 10.1081/COPD-200053377 10.1586/14737167.4.5.581 10.1378/chest.07-0898 10.1136/thx.2004.023283 10.1093/hmg/11.5.525 10.1002/gcc.10252 10.1016/j.molcel.2010.09.026 10.1164/ajrccm.160.2.9901027 10.1073/pnas.97.11.6085 10.1378/chest.126.6.1867 10.1056/NEJMoa063564 |
| ContentType | Journal Article |
| Contributor | Frankel, S Arai, T Barnes, P Lee, Hye-Seung Inoue, Yoshikazu Love, C Saggar, R Alving, Barbara Komatsu, K Sasagawa, M Brody, Alan Faile, D Young, Lisa Perez, E Moriguchi, H McKay, Roy Strange, Charlie Hayashi, S Trapnell, Bruce Krischer, Jeffrey Moss, Joel Kervitsky, D Morrison, M Takada, T Callahan, E Terada, M Kennie, K Uber, Sheri Jacobson, F Taveira-DaSilva, A Schroeder, J Colby, Thomas Korbee, Leslie Blower, W Brody, A Rosas, I Sakatani, M Nakata, Koh Okumizu, Y Nakayama, H Young, L Kaneko, C Zhang, W Inoue, Y Tachibana, K Fishbein, M Golleher, S Culver, D Meyer, Cristopher Kumagai, K Roads, T Sato, A Primack, S Haughey, M Peters, E Collier, Elaine Sugimoto, C Sato, Y Lagory, D McCormack, Frank Senior, Robert Vaughan, M McMahan, Susan Kitaichi, M Meyer, C Gold, J Ohya, A Hirohata, K McKay, R Hathaway, O Meziane, M Lynch, Joseph Starling, J Stamper, M Cohen, Marsha M Downey, G Akira, M Cripe, Timothy P Nonas, S Brown, Kevin K Ravenel, J Bailey, J Groft, Steve Tazawa, R Gitter, A Cosgrove, G Kikuyama, A Hunt, Carl Barker, Alan Lopez, P Goldberg, Hilary El-Chemaly, S Kinder |
| Contributor_xml | – sequence: 1 givenname: Steve surname: Groft fullname: Groft, Steve – sequence: 2 givenname: Barbara surname: Alving fullname: Alving, Barbara – sequence: 3 givenname: Elaine surname: Collier fullname: Collier, Elaine – sequence: 4 givenname: Carl surname: Hunt fullname: Hunt, Carl – sequence: 5 givenname: Jeffrey surname: Krischer fullname: Krischer, Jeffrey – sequence: 6 givenname: Bruce surname: Trapnell fullname: Trapnell, Bruce – sequence: 7 givenname: Frank surname: McCormack fullname: McCormack, Frank – sequence: 8 givenname: Robert surname: Senior fullname: Senior, Robert – sequence: 9 givenname: Timothy P surname: Cripe fullname: Cripe, Timothy P – sequence: 10 givenname: Sheri surname: Uber fullname: Uber, Sheri – sequence: 11 givenname: Thomas surname: Colby fullname: Colby, Thomas – sequence: 12 givenname: Cristopher surname: Meyer fullname: Meyer, Cristopher – sequence: 13 givenname: Alan surname: Brody fullname: Brody, Alan – sequence: 14 givenname: Roy surname: McKay fullname: McKay, Roy – sequence: 15 givenname: Lisa surname: Young fullname: Young, Lisa – sequence: 16 givenname: Marsha M surname: Cohen fullname: Cohen, Marsha M – sequence: 17 givenname: Hye-Seung surname: Lee fullname: Lee, Hye-Seung – sequence: 18 givenname: Leslie surname: Korbee fullname: Korbee, Leslie – sequence: 19 givenname: Susan surname: McMahan fullname: McMahan, Susan – sequence: 20 givenname: Hilary surname: Goldberg fullname: Goldberg, Hilary – sequence: 21 givenname: F surname: Jacobson fullname: Jacobson, F – sequence: 22 givenname: E surname: Peters fullname: Peters, E – sequence: 23 givenname: I surname: Rosas fullname: Rosas, I – sequence: 24 givenname: Jeffrey surname: Chapman fullname: Chapman, Jeffrey – sequence: 25 givenname: D surname: Culver fullname: Culver, D – sequence: 26 givenname: D surname: Faile fullname: Faile, D – sequence: 27 givenname: M surname: Meziane fullname: Meziane, M – sequence: 28 givenname: Charlie surname: Strange fullname: Strange, Charlie – sequence: 29 givenname: A surname: Gitter fullname: Gitter, A – sequence: 30 givenname: J surname: Ravenel fullname: Ravenel, J – sequence: 31 givenname: S surname: Sahn fullname: Sahn, S – sequence: 32 givenname: Joel surname: Moss fullname: Moss, Joel – sequence: 33 givenname: A surname: Taveira-DaSilva fullname: Taveira-DaSilva, A – sequence: 34 givenname: M surname: Vaughan fullname: Vaughan, M – sequence: 35 givenname: P surname: Barnes fullname: Barnes, P – sequence: 36 givenname: S surname: El-Chemaly fullname: El-Chemaly, S – sequence: 37 givenname: O surname: Hathaway fullname: Hathaway, O – sequence: 38 givenname: M surname: Haughey fullname: Haughey, M – sequence: 39 givenname: C surname: Love fullname: Love, C – sequence: 40 givenname: J surname: Starling fullname: Starling, J – sequence: 41 givenname: Kevin K surname: Brown fullname: Brown, Kevin K – sequence: 42 givenname: G surname: Cosgrove fullname: Cosgrove, G – sequence: 43 givenname: G surname: Downey fullname: Downey, G – sequence: 44 givenname: S surname: Frankel fullname: Frankel, S – sequence: 45 givenname: J surname: Swigris fullname: Swigris, J – sequence: 46 givenname: D surname: Kervitsky fullname: Kervitsky, D – sequence: 47 givenname: M surname: Morrison fullname: Morrison, M – sequence: 48 givenname: E surname: Perez fullname: Perez, E – sequence: 49 givenname: J surname: Schroeder fullname: Schroeder, J – sequence: 50 givenname: Yoshikazu surname: Inoue fullname: Inoue, Yoshikazu – sequence: 51 givenname: M surname: Akira fullname: Akira, M – sequence: 52 givenname: M surname: Kitaichi fullname: Kitaichi, M – sequence: 53 givenname: T surname: Arai fullname: Arai, T – sequence: 54 givenname: C surname: Sugimoto fullname: Sugimoto, C – sequence: 55 givenname: K surname: Hirohata fullname: Hirohata, K – sequence: 56 givenname: Y surname: Okumizu fullname: Okumizu, Y – sequence: 57 givenname: Y surname: Inoue fullname: Inoue, Y – sequence: 58 givenname: K surname: Kumagai fullname: Kumagai, K – sequence: 59 givenname: A surname: Kikuyama fullname: Kikuyama, A – sequence: 60 givenname: A surname: Ohya fullname: Ohya, A – sequence: 61 givenname: K surname: Tachibana fullname: Tachibana, K – sequence: 62 givenname: K surname: Komatsu fullname: Komatsu, K – sequence: 63 givenname: Y surname: Sato fullname: Sato, Y – sequence: 64 givenname: H surname: Moriguchi fullname: Moriguchi, H – sequence: 65 givenname: S surname: Hayashi fullname: Hayashi, S – sequence: 66 givenname: M surname: Sakatani fullname: Sakatani, M – sequence: 67 givenname: Koh surname: Nakata fullname: Nakata, Koh – sequence: 68 givenname: H surname: Nakayama fullname: Nakayama, H – sequence: 69 givenname: M surname: Sasagawa fullname: Sasagawa, M – sequence: 70 givenname: A surname: Sato fullname: Sato, A – sequence: 71 givenname: T surname: Takada fullname: Takada, T – sequence: 72 givenname: R surname: Tazawa fullname: Tazawa, R – sequence: 73 givenname: M surname: Terada fullname: Terada, M – sequence: 74 givenname: C surname: Kaneko fullname: Kaneko, C – sequence: 75 givenname: Alan surname: Barker fullname: Barker, Alan – sequence: 76 givenname: J surname: Gold fullname: Gold, J – sequence: 77 givenname: K surname: Kennie fullname: Kennie, K – sequence: 78 givenname: S surname: Nonas fullname: Nonas, S – sequence: 79 givenname: S surname: Primack fullname: Primack, S – sequence: 80 givenname: Joseph surname: Lynch fullname: Lynch, Joseph – sequence: 81 givenname: E surname: Callahan fullname: Callahan, E – sequence: 82 givenname: M surname: Fishbein fullname: Fishbein, M – sequence: 83 givenname: S surname: Golleher fullname: Golleher, S – sequence: 84 givenname: P surname: Lopez fullname: Lopez, P – sequence: 85 givenname: R surname: Saggar fullname: Saggar, R – sequence: 86 givenname: W surname: Blower fullname: Blower, W – sequence: 87 givenname: A surname: Brody fullname: Brody, A – sequence: 88 givenname: D surname: Lagory fullname: Lagory, D – sequence: 89 givenname: R surname: McKay fullname: McKay, R – sequence: 90 givenname: B surname: Kinder fullname: Kinder, B – sequence: 91 givenname: C surname: Meyer fullname: Meyer, C – sequence: 92 givenname: T surname: Roads fullname: Roads, T – sequence: 93 givenname: M surname: Stamper fullname: Stamper, M – sequence: 94 givenname: L surname: Young fullname: Young, L – sequence: 95 givenname: W surname: Zhang fullname: Zhang, W – sequence: 96 givenname: J surname: Bailey fullname: Bailey, J – sequence: 97 givenname: J surname: Dahlquist fullname: Dahlquist, J |
| Copyright | Copyright © 2011 Massachusetts Medical Society. All rights reserved. Copyright © 2011 Massachusetts Medical Society. 2011 |
| Copyright_xml | – notice: Copyright © 2011 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2011 Massachusetts Medical Society. 2011 |
| CorporateAuthor | MILES Trial Group National Institutes of Health Rare Lung Diseases Consortium |
| CorporateAuthor_xml | – name: MILES Trial Group – name: National Institutes of Health Rare Lung Diseases Consortium |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1056/NEJMoa1100391 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database (ProQuest) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection New England Journal of Medicine Biological Sciences ProQuest Consumer Health Database Healthcare Administration Database Medical Database Psychology Database ProQuest Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest One Psychology MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 1606 |
| ExternalDocumentID | PMC3118601 2358411881 21410393 10_1056_NEJMoa1100391 NJ201104283641707 |
| Genre | Original Article Comparative Study Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCRR NIH HHS grantid: RR019259 – fundername: NCRR NIH HHS grantid: 1UL1RR026314 01 – fundername: CIHR – fundername: NCRR NIH HHS grantid: U54 RR019259 – fundername: NHLBI NIH HHS grantid: R01 HL085453 – fundername: NCRR NIH HHS grantid: UL1 RR026314 – fundername: NCRR NIH HHS grantid: RR019498 – fundername: FDA HHS grantid: FD003362 – fundername: FDA HHS grantid: R01 FD003362 – fundername: NCRR NIH HHS grantid: U54 RR019498 – fundername: National Center for Research Resources : NCRR grantid: U54 RR019259-05 || RR – fundername: National Center for Research Resources : NCRR grantid: U54 RR019498-05 || RR – fundername: National Center for Research Resources : NCRR grantid: UL1 RR026314-03 || RR |
| GroupedDBID | - 0R 0WA 123 186 1AW 1KJ 1VV 29N 2KS 2WC 34G 39C 3O- 3V. 4 4.4 53G 55 5D0 5RE 68V 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI 8RP AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AASXA AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQES ABQIJ ABUFD ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ACVYA ADBBV ADCBC AENEX AETEA AFDAS AFFNX AFHKK AFKRA AGNAY AHMBA AHVBC AIKQT AJJEV AJYGW ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCR BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS EJD ET EX3 F20 F5P FD8 FM. FYUFA G8K GJ GNUQQ GUQSH H13 HCIFZ HZ IH2 K-O K78 KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC MVM N9A NEJ O0- O9- OK1 OMK OVD P-O P2P PADUT PCD PEA PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TN5 TWZ U1N UCV UKR UMD UQL VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZKB ZR0 ZXP --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 1CY 36B 6TJ AAMNW AAYXX ABBLC ABCQX ABDPE ABDQB ABJNI ACKOT ACPFK ADRHT ADUKH ADXHL AERZD AFOSN AGFXO AGHSJ ALIPV BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W NAPCQ PHGZM PHGZT PSYQQ TEORI TUQ UKHRP XOL YFH YR2 YR5 YYP ZCA ZVN ~KM CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7XB BEC K0Y PKEHL Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c509t-daf86341895806008e47da697a5d396003c2cd2d7bbd8f89a29e8b923f54e9a63 |
| IEDL.DBID | 7X7 |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Thu Aug 21 18:01:49 EDT 2025 Thu Jul 10 21:58:52 EDT 2025 Sat Aug 23 12:48:01 EDT 2025 Mon Jul 21 06:04:00 EDT 2025 Tue Jul 01 02:36:52 EDT 2025 Thu Apr 24 23:07:07 EDT 2025 Wed Nov 11 00:33:09 EST 2020 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c509t-daf86341895806008e47da697a5d396003c2cd2d7bbd8f89a29e8b923f54e9a63 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-General Information-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-3 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 The members of the Rare Lung Diseases Consortium and the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus (MILES) trial group are listed in the Supplementary Appendix, available at NEJM.org. |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1100391?articleTools=true |
| PMID | 21410393 |
| PQID | 868663427 |
| PQPubID | 40644 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3118601 proquest_miscellaneous_864192309 proquest_journals_868663427 pubmed_primary_21410393 crossref_citationtrail_10_1056_NEJMoa1100391 crossref_primary_10_1056_NEJMoa1100391 mms_nejm_10_1056_NEJMoa1100391 |
| ProviderPackageCode | DCD 7FN CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-04-28 |
| PublicationDateYYYYMMDD | 2011-04-28 |
| PublicationDate_xml | – month: 04 year: 2011 text: 2011-04-28 day: 28 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2011 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | r020 r021 Taveira-DaSilva AM (r001) 2006; 13 r022 r023 r017 r018 r019 r013 r014 r015 r016 Johnson SR (r004) 1999; 160 Khanna D (r025) 2010; 28 r010 r011 r012 r006 r007 r008 Larson JL (r024) 1998; 6 r009 r002 r003 r026 r005 r027 21410388 - N Engl J Med. 2011 Apr 28;364(17):1670-1. doi: 10.1056/NEJMe1102290. 21774717 - N Engl J Med. 2011 Jul 21;365(3):271-2; author reply 272. doi: 10.1056/NEJMc1106358. 21774718 - N Engl J Med. 2011 Jul 21;365(3):271; author reply 272. doi: 10.1056/NEJMc1106358. |
| References_xml | – volume: 6 start-page: 55 year: 1998 ident: r024 publication-title: J Nurs Meas doi: 10.1891/1061-3749.6.1.55 – ident: r021 doi: 10.1378/chest.10-0573 – ident: r017 doi: 10.1002/gcc.20118 – ident: r014 doi: 10.1053/hupa.2003.50 – ident: r015 doi: 10.1074/jbc.M202678200 – ident: r019 doi: 10.1056/NEJMc072500 – ident: r023 doi: 10.1378/chest.130.4.1117 – ident: r013 doi: 10.1164/rccm.200208-969OC – ident: r011 doi: 10.1097/01.pas.0000172192.25295.45 – ident: r003 doi: 10.1097/00005792-199909000-00004 – ident: r008 doi: 10.1073/pnas.0407971101 – ident: r012 doi: 10.1097/01.pas.0000126859.70814.6d – ident: r020 doi: 10.1056/NEJMe0707153 – ident: r027 doi: 10.1164/rccm.200409-1298OC – volume: 13 start-page: 276 year: 2006 ident: r001 publication-title: Cancer Control doi: 10.1177/107327480601300405 – ident: r022 doi: 10.1081/COPD-200053377 – ident: r026 doi: 10.1586/14737167.4.5.581 – ident: r002 doi: 10.1378/chest.07-0898 – ident: r006 doi: 10.1136/thx.2004.023283 – ident: r016 doi: 10.1093/hmg/11.5.525 – volume: 28 start-page: S55 year: 2010 ident: r025 publication-title: Clin Exp Rheumatol – ident: r007 doi: 10.1002/gcc.10252 – ident: r010 doi: 10.1016/j.molcel.2010.09.026 – volume: 160 start-page: 628 year: 1999 ident: r004 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.160.2.9901027 – ident: r009 doi: 10.1073/pnas.97.11.6085 – ident: r005 doi: 10.1378/chest.126.6.1867 – ident: r018 doi: 10.1056/NEJMoa063564 – reference: 21774717 - N Engl J Med. 2011 Jul 21;365(3):271-2; author reply 272. doi: 10.1056/NEJMc1106358. – reference: 21774718 - N Engl J Med. 2011 Jul 21;365(3):271; author reply 272. doi: 10.1056/NEJMc1106358. – reference: 21410388 - N Engl J Med. 2011 Apr 28;364(17):1670-1. doi: 10.1056/NEJMe1102290. |
| SSID | ssj0000149 |
| Score | 2.5730557 |
| Snippet | This trial showed that in patients with lymphangioleiomyomatosis (LAM), a progressive, cystic lung disease in women, sirolimus therapy was associated with... Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin... Background Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of... |
| SourceID | pubmedcentral proquest pubmed crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1595 |
| SubjectTerms | Adult Double-Blind Method Female Forced Expiratory Volume - drug effects Human subjects Humans Intention to Treat Analysis Kinases Lungs Lymphangioleiomyomatosis - drug therapy Lymphangioleiomyomatosis - physiopathology Medication Adherence Middle Aged Observation Quality of Life Sirolimus - adverse effects Sirolimus - blood Sirolimus - therapeutic use TOR Serine-Threonine Kinases - antagonists & inhibitors Vascular endothelial growth factor Vital Capacity - drug effects Womens health |
| Title | Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis |
| URI | http://dx.doi.org/10.1056/NEJMoa1100391 https://www.ncbi.nlm.nih.gov/pubmed/21410393 https://www.proquest.com/docview/868663427 https://www.proquest.com/docview/864192309 https://pubmed.ncbi.nlm.nih.gov/PMC3118601 |
| Volume | 364 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB6aBEovpenTTbvoUHqqiC35IUOgtGFDKE0oTQN7M7IlpS61nNa7h_33mdnVmmxoevFFg5FnJH0zmvE3AO8QEp0U2nAdi4anxtW8tqXhBqFJae0SmdD_zmfn-ell-mWWzUJtzhDKKjdn4uqgNn1Dd-SHKlcIjqkoPl7_4dQ0ipKroYPGDuwRcxlVdBWz4hZ7VPB-wwVSoNhEyD-kRvO9Jro0WSZbkLTTdcO_vM27RZO3UOjkCTwO7iP7tLb3Pjyw_ik8PAsJ8mdwNCVKCN0smfaGXWhn50vWO3bRUneebjGw1rOvSzSh9leUk2_7btmj19oP7fAcLk-mP45PeWiQwBvE-Tk32inUSaLw22P0XJRNC6PzstCZkRiaxLIRjRGmqGujnCq1KK2q0aVzWWpLncsXsOt7b18BczW9x4oY4T_NDAZi0maibhLtshyjxAg-bHRUNYE9nJpY_K5WWewsr7ZUGsH7Ufx6TZtxn-AEFV55-6u7T-BgY4sqbK-hGhdDBGwcxX1ByQ7tbb8gEcpvy7iM4OXacONEBNW2ylJGUGyZdBQgyu3tEd_-XFFvS4zHMIR9_d9JHcCj9c1zyoV6A7vzvwv7Fl2XeT1ZLVB8quNkAnufp-ffvt8AvtXtdg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB61Wwm4IN6EQvEBOBE1sfNwJBDisdWW7q4QbaXeUie2aSriFLIrlB_Ff2S8eaiLKLeePbKsmbHnG4_9DcALDImaUSFd4dHcDaTO3Ewl0pUYmrgQ2me-_e88m0eT4-DzSXiyAb_7vzD2WWV_Jq4Oalnl9o58l0ccg2NA43cXP1zbNMoWV_sOGq1XHKjmF2Zs9dv9T2jel5TujY8-TtyuqYCbY2xcuFJojvP4PAm5h9GeqyCWIkpiEUqGcN5jOc0llXGWSa55ImiieIYwSIeBSkTEcN5N2AoYZjIj2Pownn_5eomvqsPb3ZVVR-qJIGPXtravhCVoY4m_FgQ3y7L-F779-5nmpbi3dwdud4CVvG897C5sKHMPbsy6kvx9eDO2JBQib4gwkhwKrRYNqTQ5LGw_oHJZk8KQaYNOI8w3-wqgqMqmQpxc1UX9AI6vRXsPYWQqox4D0ZmdR1EPAUcQSkz9mApplvtChxHmpQ687nWU5h1fuW2b8T1d1c3DKF1TqQOvBvGLlqjjKsEdVHhq1Hl5lcB2b4u029B1OrifA2QYxZ1oyyvCqGppRWxFnXmJA49aww0LofY1LUuYA_GaSQcBS_K9PmKKsxXZN8MMEF3tyX8X9RxuTo5m03S6Pz_YhlvtvXfgUv4URoufS_UMgdMi2-nclcDpde-QP65oKKU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB61Raq4VOUdCsUH4ETUxI4TRwIhRLtq6UNIpdLeghPbNFWTlGZXKD-Nf8d440RdRLn17JFlzcPzjWc8A_AaXaJhVCpfBrTwI2VyP9ep8hW6JiGlCVlo_zsfn8T7Z9GXKZ-uwO_hL4wtqxzuxMVFrZrCvpHviFigc4wwUjeuKuLr7uTj1U_fDpCyidZhmkavIYe6-4XRW_vhYBdF_YbSyd63z_u-GzDgF-gnZ76SRuCeoUi5CNDzCx0lSsZpIrliCO0DVtBCUZXkuRJGpJKmWuQIiQyPdCpjhvuuwr2E8dCaWDJNbnSucsjbPV659p4IN3bskPtG2lZtLA2X3OFqVbX_Qrp_F2ze8ICTTdhw0JV86nXtAazo-iGsH7vk_CN4v2fbUciiI7JW5FQaPetIY8hpaScDVfOWlDU56lB9ZP3D1gOUTdU1iJibtmwfw9md8O4JrNVNrZ8BMbndR9MAoUfEFQaBTHOaF6E0PMYI1YN3A4-ywnUutwM0LrNFBp3H2RJLPXg7kl_1LTtuI9xGhme1vqhuI9gaZJE5026zURE9IOMq2qRNtMhaN3NLYnPrLEg9eNoLbjwItXW1LGUeJEsiHQlsu-_llbo8X7T9ZhgLYvj8_L-HegXraBfZ0cHJ4Rbc7x_AI5-KF7A2u57rl4igZvn2QlcJfL9r4_gDaOErdQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+Safety+of+Sirolimus+in+Lymphangioleiomyomatosis&rft.jtitle=The+New+England+journal+of+medicine&rft.au=McCormack%2C+Francis+X.&rft.au=Inoue%2C+Yoshikazu&rft.au=Moss%2C+Joel&rft.au=Singer%2C+Lianne+G.&rft.date=2011-04-28&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=364&rft.issue=17&rft.spage=1595&rft.epage=1606&rft_id=info:doi/10.1056%2FNEJMoa1100391&rft.externalDBID=n%2Fa&rft.externalDocID=10_1056_NEJMoa1100391 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |